Cardiometabolic Medicine
The need for consistent updates and agile content is imperative for today’s clinician to remain current on the continuum of scientific data. In no therapeutic area is this more essential than in “Cardiometabolic Medicine,” a new term meant to encompass the interconnected and debilitating diagnoses of diabetes mellitus, heart failure, coronary artery disease/acute coronary syndrome, progressive renal insufficiency, and related disorders such as hypertension, hyperlipidemia, and hyperkalemia. These areas are subject to frequent pivotal trial publications, guidelines updates, FDA action, and outcomes assessments.
Our Tweetorials
Your new source for free CE/CME via Twitter!
Each program provides 0.5hr – 1.0hr credit for physicians, pharmacists, and nurses.
UPDATE FROM ESC24: NEW DATA ON FACTOR XI/XIa INHIBITION IN ATRIAL FIBRILLATION
2) Our returning esteemed guest faculty is C. Michael Gibson MD @CMichaelGibson, Non-Profit Founder/Leader &❤️ Doc from @harvardmed. #cmg will...
UPDATE FROM ESC24: NEW DATA ON NON-STATIN LIPID LOWERING THERAPIES AND REDUCED CV RISK
2) We are pleased and honored to welcome back our esteemed guest faculty is C. Michael Gibson MD @CMichaelGibson, Non-Profit Founder/Leader...
Journal Club: Andexanet alfa versus PCC products for factor Xa inhibitor bleeding: A systematic review with meta-analysis
2) This is an @cardiomet_CE #JournalClub on "Andexanet alfa versus PCC products for factor Xa inhibitor bleeding: A systematic review with...
IMPACT AND OPTIMAL MANAGEMENT OF FACTOR Xa INHIBITOR DOAC-RELATED MAJOR GASTROINTESTINAL BLEEDING
2) We spend alot of time discussing in these programs the management of the most feared 🩸 complication of #DOAC therapy--#ICH. We respect it! But we...
Early, Optimal Management of CKD and Cardiorenal Disease to Prevent Disease Progression and Improve Outcomes
2) The program is intended for #HCPs & is supported by an independent educational grant from Bayer. Statement of accreditation and faculty...
LATE-BREAKING DATA FROM ESOC2024: Clinical Consequences of Hematoma Expansion and Thrombotic Events in Patients with ICH Associated with Factor Xa-Inhibitor Treatment – Secondary Analysis from ANNEXA-I
2) Our first-time expert author is #ANNEXa_I investigator David Seiffge MD @DavidSeiffge, Vascular neurologist at Inselspital Bern 🇨🇭#FOAMed #FOAMcc...
Albuminuria: The Canary in the Coal Mine of Kidney and Cardiorenal Disease
2) The program is intended for #HCPs & is supported by an independent educational grant from Bayer. Statement of accreditation and faculty...
ACUTE PSVT MANAGEMENT UPDATES, “LIVE” FROM ACC24
2) Our expert faculty from here at #ACC24 is Narendra Singh MD @heartdrsingh, #cardiologist & faculty at both @MCG_AUG and College of Health...
NOTABLE HIGHLIGHTS “LIVE” FROM ACC24: ADVANCES IN NON-STATIN LIPID THERAPY
2) Not all pts w/ #hyperlipidemia & associated #CV risk can tolerate #statins, & others are statin-refractory. Much research on non-statin...
Code ICH: A Call to Action
1b) @AnticoagPharmD is Systems Director of Anticoagulation Services and also is the Co-Chair of the @NATF Thrombosis Medical Advisory Board &...
@Cardiomet_CE on Twitter
Your only source for ACCREDITED SoMe-delivered
serialized professional cardiometabolic education. Physicians, nurses, pharmacists–come one, come all!
On Twitter at @cardiomet_ce, we present a series of tweetorials, Twitter-delivered case studies, and Twitter Journal Clubs, each accredited for 0.5hr – 1.0hr CE/CME. Programs are presented by expert faculty in engaging and fully interactive format. Our unique program harnesses the reach, up-to-the-minute currency, and accessibility of social media to deliver a constant flow of accredited, interactive, expert-delivered educational programs to a multidisciplinary and interprofessional audience of engaged clinicians.